Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
Jasper Therapeutics Analyst Ratings
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
BTIG Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $90
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating
Buy Rating on Jasper Therapeutics Focused on Briquilimab's Efficacy With Reduced Toxicity
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $70
Jasper Therapeutics (JSPR) Gets a Buy From Stifel Nicolaus
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Cuts Target Price to $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $55 to $90
RBC Capital Keeps Their Buy Rating on Jasper Therapeutics (JSPR)
Buy Rating Reaffirmed for Jasper Therapeutics on Strong Clinical Performance and Market Potential
Jasper Therapeutics Analyst Ratings
Jasper Therapeutics Analyst Ratings
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65
Evercore Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65
Jasper Therapeutics (JSPR) Gets a Buy From Evercore ISI